Baltimore’s Legal Setback in Opioid Crisis Battle as Court Overturns $152M Ruling

BALTIMORE — The Maryland Supreme Court has overturned Baltimore’s $152 million opioid verdict against two major drug distributors, delivering a significant setback to the city’s efforts to hold pharmaceutical companies accountable for their role in the opioid epidemic. In a ruling issued last week, the state’s highest court vacated the 2025 judgment against McKesson Corp. And Cencora (formerly AmerisourceBergen), sending the case back to the Circuit Court for Baltimore City for further proceedings.

Court Cites Narrowing of Public Nuisance Claims

The Maryland Supreme Court’s decision hinged on a recent legal precedent that restricts the use of public nuisance claims in opioid litigation. The court determined that Baltimore’s case, which alleged the distributors created a public nuisance by oversupplying prescription opioids, did not meet the newly established legal standards. The ruling aligns with a broader trend in state and federal courts, where judges have increasingly rejected public nuisance arguments in opioid-related lawsuits, favoring more narrowly tailored legal theories.

The original verdict, awarded in October 2025, marked one of the largest opioid settlements in Maryland history. Baltimore had argued that McKesson and Cencora contributed to the city’s opioid crisis by failing to monitor and report suspiciously large orders of prescription painkillers, which prosecutors said flooded communities and fueled addiction. The $152 million award was intended to fund addiction treatment programs, overdose prevention initiatives, and other public health efforts in the city.

Distributors Deny Wrongdoing, City Vows to Press Forward

Both McKesson and Cencora have consistently denied any wrongdoing, arguing that they complied with federal regulations governing the distribution of controlled substances. In a joint statement following the ruling, the companies reiterated their commitment to combating opioid abuse while emphasizing their adherence to legal and regulatory requirements. “We remain focused on supporting efforts to address the opioid crisis through collaboration with public health officials and community organizations,” the statement said.

Baltimore officials, however, have signaled their intent to continue pursuing the case. City Solicitor Ebony Thompson called the ruling “a temporary setback” and confirmed that Baltimore would explore all available legal options, including the possibility of amending its complaint to align with the court’s guidance. “The opioid epidemic has devastated families and communities across our city, and we are determined to hold those responsible accountable,” Thompson said in a statement released Friday.

Broader Implications for Opioid Litigation

The Maryland Supreme Court’s decision reflects a growing judicial skepticism toward public nuisance claims in opioid cases, a legal strategy that has yielded mixed results nationwide. While some states, including Oklahoma and New York, have secured multibillion-dollar settlements from pharmaceutical companies, others have seen their cases dismissed or overturned on similar grounds. Legal experts say the ruling could influence ongoing litigation in other jurisdictions, particularly where plaintiffs have relied on public nuisance theories to seek damages.

In Maryland, the case will now return to the lower court, where Baltimore may attempt to reframe its arguments under a different legal theory, such as negligence or violations of state consumer protection laws. The city’s legal team has not yet indicated whether it will seek to amend its complaint or pursue an appeal of the Supreme Court’s decision.

Opioid Crisis Continues to Exact Heavy Toll on Baltimore

The opioid epidemic remains a pressing public health crisis in Baltimore, where overdose deaths have surged in recent years. According to data from the Maryland Department of Health, the city recorded more than 1,200 overdose fatalities in 2025 alone, a record high. The majority of these deaths involved fentanyl, a synthetic opioid significantly more potent than heroin. City officials have warned that the crisis has strained local resources, including emergency medical services, addiction treatment programs, and law enforcement.

Baltimore’s legal battle against opioid distributors is part of a broader national effort to secure funding for addiction treatment and prevention. Across the United States, states, counties, and municipalities have filed thousands of lawsuits against pharmaceutical manufacturers, distributors, and retailers, seeking compensation for the public health and economic costs of the epidemic. While some cases have resulted in substantial settlements—including a $26 billion agreement with Johnson & Johnson and three major distributors in 2021—others have been dismissed or remain tied up in lengthy legal proceedings.

The Maryland Supreme Court’s ruling does not preclude Baltimore from pursuing other legal avenues, but it underscores the challenges plaintiffs face in holding pharmaceutical companies accountable through public nuisance claims. As the case returns to the circuit court, city officials and legal observers will be watching closely to see whether Baltimore can adapt its strategy to meet the court’s standards—or whether the decision will further limit the legal options available to communities grappling with the opioid crisis.